Ruxolitinib (INCB18424)

目录号: GC14191纯度: >98.00%同义词: 芦可替尼; INCB18424

Ruxolitinib (INCB18424)作为一种抑制剂，能够抑制Janus相关激酶(JAKs)JAK1和JAK2, IC50 分别为 3.3 nM 和 2.8 nM，Ruxolitinib介导对造血和免疫功能重要的若干细胞因子和生长因子信号。

Cas No.: 941678-49-5

规格	价格	库存	数量
5mg	¥504.00	现货	1
25mg	¥1,176.00	现货	1
100mg	¥2,027.00	现货	1
10mM (in 1mL DMSO)	¥494.00	现货	1

电话: 400-920-5774Email: sales@glpbio.cn

文献被引

本产品暂无引用记录;以下为 GlpBio 产品在 Nature / Cell / Science 等顶刊的客户引用样例

Nature
641, 529–536 (2025)
Nature
628, 630–638 (2024)
Nature
632, 686–694 (2024)
Nature
618, 1017–1023 (2023)
Nature
610, 366–372 (2022)
Cell
187(9):2288-2304 (2024)
Cell
183(7):1867-1883 (2020)
Science
388(6745) (2025)
Science
387(6739) (2025)
Science
387(6734) (2025)
Cell Research
35, 97–116 (2025)
Cell Research
34, 683–706 (2024)
Cell Research
33, 273–287 (2023)
Cell Research
33, 546–561 (2023)
Cell Research
33, 904–922 (2023)
Cell Research
31, 1291–1307 (2021)

产品描述 Description

Ruxolitinib (INCB18424), as an inhibitor, inhibits Janus-associated kinases (JAKs)JAK1 and JAK2 with IC₅₀ values of 3.3 nM and 2.8 nM, respectively. Ruxolitinib mediates several cytokine and growth factor signaling important for hematopoietic and immune function^[1-3].

Ruxolitinib (INCB18424) (500nM-50μM;30min) significantly inhibited the production of IL-6, TNF-α and MCP-1 as induced by A23817 and substance P in HMC1 cells^[4]. Ruxolitinib(0-400nM; 3days) reduced the level of cytokine release in CAR-T cells^[5].

Ruxolitinib (INCB18424) (30 mg/kg; p.o.; twice a day 14 days) treatment alleviated renal damage in UUO mice^[6]. Ruxolitinib(twice daily by oral gavage; 2 weeks) treatment improves viability and splenomegaly in a JAK2^V617F-driven model of malignant disease^[3]. Treatment of Fancc^-/- mice with ruxolitinib(45 mg/kg; i.p; 5 days/week) decreased anemia, enhanced granulocytosis, delayed clonal progression and prolonged survival during repeated emergency granulopoiesis episodes^[7].

References:

[1]. Becker H, Engelhardt M, et,al. Ruxolitinib. Recent Results Cancer Res. 2014;201:249-57. doi: 10.1007/978-3-642-54490-3_16. PMID: 24756798.

[2]. Ajayi S, Becker H, et,al. Ruxolitinib. Recent Results Cancer Res. 2018;212:119-132. doi: 10.1007/978-3-319-91439-8_6. PMID: 30069628.

[3]. Quintás-Cardama A, Vaddi K, et,al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010 Apr 15;115(15):3109-17. doi: 10.1182/blood-2009-04-214957. Epub 2010 Feb 3. PMID: 20130243; PMCID: PMC3953826.

[4]. Hermans MAW, Schrijver B, et,al. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release. Clin Exp Allergy. 2018 Nov;48(11):1412-1420. doi: 10.1111/cea.13217. Epub 2018 Aug 3. PMID: 29939445.

[5]. Xu N, Yang XF, et,al. Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells. Biochem Biophys Res Commun. 2022 Mar 5;595:54-61. doi: 10.1016/j.bbrc.2022.01.070. Epub 2022 Jan 20. PMID: 35101664.

[6]. Bai Y, Wang W, et,al. Ruxolitinib Alleviates Renal Interstitial Fibrosis in UUO Mice. Int J Biol Sci. 2020 Jan 1;16(2):194-203. doi: 10.7150/ijbs.39024. PMID: 31929748; PMCID: PMC6949153.

[7]. Hasan S, Hu L, et,al. Ruxolitinib ameliorates progressive anemia and improves survival during episodes of emergency granulopoiesis in Fanconi C-/- mice. Exp Hematol. 2022 May;109:55-67.e2. doi: 10.1016/j.exphem.2022.03.001. Epub 2022 Mar 9. PMID: 35278531; PMCID: PMC9064927.

Ruxolitinib (INCB18424)作为一种抑制剂，能够抑制Janus相关激酶(JAKs)JAK1和JAK2, IC₅₀ 分别为 3.3 nM 和 2.8 nM，Ruxolitinib介导对造血和免疫功能重要的若干细胞因子和生长因子信号^[1-3]。

Ruxolitinib (INCB18424) (500nM-50μM;30min)显著抑制A23817和substance P诱导的HMC1细胞中IL-6、TNF-α和MCP-1的产生^[4]。Ruxolitinib (0-400nM; 3days)降低CAR-T细胞中细胞因子的释放水平^[5]。

Ruxolitinib (INCB18424)治疗(30 mg/kg; p.o.; twice a day 14 days)可减轻UUO小鼠肾损害^[6]。Ruxolitinib治疗(twice daily by oral gavage; 2 weeks)改善JAK2^V617F-driven的恶性疾病小鼠的生存能力和脾肿大情况^[3]。用Ruxolitinib (45 mg/kg; i.p; 5 days/week)治疗Fancc^-/-小鼠可减少贫血，增强粒细胞功能，延迟克隆进展，延长反复紧急粒细胞生成发作期间的生存期^[7]。

实验参考方法 Experimental Reference Method

Cell experiment^[1]:
Cell lines	HMC1 cells
Preparation method	Cells were seeded in a 96-well plate at 2×10⁵ cells in 200 μL culture medium per condition. Subsequently, the cells were incubated for 30 minutes with ruxolitinib before stimulating them with 1 μmol/L of A23187 or 5 μmol/L of substance P. TNF-α levels in the supernatant were measured after 6 hours of stimulation, and MCP-1 and IL-6 levels were measured after 24 hours of stimulation.
Reaction Conditions	500nM-50μM;30min
Applications	Ruxolitinib significantly inhibited the production of IL-6, TNF-α and MCP-1 as induced by A23817 and substance P in HMC1 cells.
Animal experiment ^[2]:
Animal models	Male C57BL/6 mice
Preparation method	Mice were randomly assigned to three groups with 5 mice in each group as follows: (1) Sham-operated mice with vehicle (Sham); (2) Unilateral ureteral obstruction (UUO) mice with vehicle (UUO); (3) UUO mice treated with Ruxolitinib (UUO+RUX). To establish UUO model, mice were given general anesthesia by intraperitoneal injection of pentobarbital (50mg/kg body weight). The left ureter was exposed via a left flank incision, ligated with 4-0 silk at two points, and cut between the 2 ligation points. The Sham-operated group had no ligation. For in vivo experiments, Ruxolitinib was dissolved in PEG300/dextrose 5%l in a ratio of 1:3 (PEG/dex) and administered to mice by oral gavage at a dosage of 30 mg/kg twice daily for 14 days immediately after UUO or Sham-operation. The Sham and UUO group received PEG/dex alone as vehicle. Thel mice were sacrificed at days 14 after surgery.
Dosage form	30 mg/kg; p.o.; twice a day 14 days
Applications	Ruxolitinib treatment alleviated renal damage in UUO mice.
References: [1]. Hermans MAW, Schrijver B, et,al. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release. Clin Exp Allergy. 2018 Nov;48(11):1412-1420. doi: 10.1111/cea.13217. Epub 2018 Aug 3. PMID: 29939445. [2]. Bai Y, Wang W, et,al. Ruxolitinib Alleviates Renal Interstitial Fibrosis in UUO Mice. Int J Biol Sci. 2020 Jan 1;16(2):194-203. doi: 10.7150/ijbs.39024. PMID: 31929748; PMCID: PMC6949153.

产品文档 Product Documents

批次：Purity:>98.00%

化学性质Chemical Properties

CAS 号

941678-49-5

同义词

芦可替尼; INCB18424

化学名

(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile

SMILES

C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3

分子式

C₁₇H₁₈N₆

分子量

306.37 g/mol

溶解性

≥ 15.32mg/mL in DMSO

保存条件

Store at -20°C

General tips

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
为了提高溶解度，请将管子加热至 37°C，然后在超声波浴中震荡一段时间。

Shipping Condition

评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备 RT，或根据请求配备蓝冰。

计算工具摩尔浓度 / 稀释 / 分子量 / 单位换算 / 体内配方 / 溶解度

质量 (Mass)

体积 (Volume)

浓度 (Concentration)

分子量 (MW)

g/mol